Ascentage Pharma announces annual general meeting

• Ascentage Pharma AGM set for Suzhou, China on May 20, 2026.
• Shareholders will vote on adoption of audited consolidated financial statements for fiscal 2025.
• Meeting will consider re-election of three directors, including two non-executive directors and one independent non-executive director.
• Board will seek authority to set directors’ remuneration, reappoint Ernst & Young as auditor, and fix auditor remuneration.
• Resolutions include mandates to issue shares up to 20%, repurchase shares up to 10%, extend issuance mandate by shares repurchased, and adopt amended and restated memorandum and articles of association.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260429-12131648), on April 28, 2026, and is solely responsible for the information contained therein.